The National Genomic Test Directory for Cancer  specifies the genomic tests commissioned by NHS England for cancer, eligibility criteria, and how to order them.

Access to genomic services for HaemOnc patients will continue to be through your Specialist Integrated Haematological Malignancy Diagnostic Service (SIHMDS). An SIHMDS incorporates all pathology specialisms associated with haematological malignancy diagnosis, including:

  • morphology
  • histology (including immunohistochemistry)
  • immunophenotyping
  • cytogenetics
  • FISH
  • molecular studies.

Central and South Genomics covers three SIHMDS groups:

West Midlands SIHMDS group

Oxford SIHMDS group

Wessex SIHMDS group

Genomic haemato-oncology diagnostics are funded centrally by NHSE and so referring Trusts will not be charged for these services if they refer testing to their designated local GLH. Please note that non-genetic activity carried out within an SIHMDS is funded separately and will still be charged for.

Whole Genome Sequencing (WGS) is commissioned by NHS England for a sub-group of patients with haematological cancers. More information and test information sheets can be accessed by clicking here.

Date Test Code Test Name Target Gene(s) [essential] Test Scope Technology Further Eligibility Criteria Essential targets only
6 March 2026 M218.1 Multi-target NGS panel – small variant (BRCA1, BRCA2) for somatic/tissue testing BRCA1, BRCA2 Small variant detection Panel Patient is eligible for NICE approved PARP inhibitor and has a diagnosis of metastatic castration-resistant prostate cancer. Somatic analysis should be performed first, germline analysis (R444.2) should only be performed should there be insufficient tissue, or the somatic analysis has failed.
Date Test Code Test Name Target Gene(s) [essential] Test Scope Technology Further Eligibility Criteria Essential targets only
6 March 2026 M218.1 Multi-target NGS panel – small variant (BRCA1, BRCA2) for somatic/tissue testing BRCA1, BRCA2 Small variant detection Panel Patient is eligible for NICE approved PARP inhibitor and has a diagnosis of metastatic castration-resistant prostate cancer. Somatic analysis should be performed first, germline analysis (R444.2) should only be performed should there be insufficient tissue, or the somatic analysis has failed.
Date Test Code Test Name Target Gene(s) [essential] Test Scope Technology Further Eligibility Criteria Essential targets only
6 March 2026 M218.1 Multi-target NGS panel – small variant (BRCA1, BRCA2) for somatic/tissue testing BRCA1, BRCA2 Small variant detection Panel Patient is eligible for NICE approved PARP inhibitor and has a diagnosis of metastatic castration-resistant prostate cancer. Somatic analysis should be performed first, germline analysis (R444.2) should only be performed should there be insufficient tissue, or the somatic analysis has failed.